Biotechnology Chinese biologics contract manufacturing organization (CMO) WuXi Biologics will continue to invest in capacity expansion in the USA and European Union to speed up its business growth, said the firm’s chief executive Chris Chen at a media conference held in Shanghai this month, reports The Pharma Letter’s local correspondent Wang Fangqing. 29 March 2019